Clinical trial
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
NCT04526509 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
- Lead sponsor
- Adaptimmune
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 21, 2020
- Completion date
- June 8, 2023
- Enrollment
- 12 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.